Carisma Therapeutics, Inc. CARM
Set alert
0.00 USD 0.00 +40.00%
At close · Oct 29
0.12 +0.12 +16,771.43%
After hours · Oct 29, 4:00 PM ET
0.0263 Day range 0.0324
0.0001 52-week range 0.0678
- YTD
- -98.37%
- 1 year
- -98.55%
- Open
- 0.02725
- Prev close
- 0.0005
- Mkt cap
- 29.29K
- Vol
- 10.30K
- Avg vol
- 31.31K
- EPS
- 0.19
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0263
- High
- 0.0324
- Forward P/E
- -0.43
- Beta
- 0.00
- Short ratio
- 2.88
- Inst. own
- 31.47%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.85396
- 200-d avg
- 1.25
- 1y target
- 4.57
2Y chart
Events in this range
- Nov 7, 2024Earnings: -0.31; estimate -0.31; surprise 0%
- Dec 9, 2024Rating: D. Boral Capital · Buy → Buy
- Dec 10, 2024Downgrade: BTIG · Buy → Neutral
- Dec 11, 2024Downgrade: Evercore ISI Group · Outperform → In-Line
- Dec 12, 2024Downgrade: Baird · Outperform → Neutral
- Dec 12, 2024Rating: D. Boral Capital · Buy → Buy
- Dec 16, 2024Downgrade: HC Wainwright & Co. · Buy → Neutral
Signals (59)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 21, 2026 | 1 week ago |
| SMA: Bearish | Oct 16, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 16, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 15, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 15, 2026 | 2 weeks ago |
| RSI: Overbought | Oct 15, 2026 | 2 weeks ago |
| MACD: Buy Signal | Aug 12, 2026 | 2 months ago |
| SMA: Bearish | Jul 20, 2026 | 3 months ago |
| MACD: Sell Signal | Jun 26, 2026 | 4 months ago |
| SMA: Bullish | Jun 16, 2026 | 4 months ago |
| SMA: Bearish | Jun 11, 2026 | 4 months ago |
| SMA: Bullish | Jun 10, 2026 | 4 months ago |
| SMA: Bearish | Jun 9, 2026 | 4 months ago |
| SMA: Bullish | Jun 8, 2026 | 4 months ago |
| RSI: Overbought | Jun 8, 2026 | 4 months ago |
| MACD: Buy Signal | May 7, 2026 | 5 months ago |
| MACD: Sell Signal | Apr 20, 2026 | 6 months ago |
| RSI: Oversold | Apr 20, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 10, 2026 | 6 months ago |
| SMA: Bearish | Mar 10, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 10, 2026 | 7 months ago |
| SMA: Bullish | Mar 9, 2026 | 7 months ago |
| SMA: Bearish | Mar 6, 2026 | 7 months ago |
| SMA: Bullish | Mar 5, 2026 | 8 months ago |
| SMA: Bearish | Mar 2, 2026 | 8 months ago |
| SMA: Bullish | Feb 27, 2026 | 8 months ago |
| SMA: Bearish | Feb 25, 2026 | 8 months ago |
| SMA: Bullish | Feb 23, 2026 | 8 months ago |
| MACD: Buy Signal | Oct 29, 2025 | 1 year ago |
| RSI: Oversold | Oct 10, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 18, 2025 | 1 year ago |
| SMA: Bearish | Sep 17, 2025 | 1 year ago |
| SMA: Bearish | Sep 11, 2025 | 1 year ago |
| SMA: Bullish | Sep 5, 2025 | 1 year ago |
| SMA: Bullish | Sep 5, 2025 | 1 year ago |
| SMA: Bearish | Sep 4, 2025 | 1 year ago |
| SMA: Bearish | Sep 3, 2025 | 1 year ago |
| SMA: Bullish | Sep 2, 2025 | 1 year ago |
| SMA: Bullish | Sep 2, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 2, 2025 | 1 year ago |
| RSI: Overbought | Sep 2, 2025 | 1 year ago |
| RSI: Oversold | Aug 21, 2025 | 1 year ago |
| SMA: Bearish | Jul 29, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 24, 2025 | 1 year ago |
| RSI: Overbought | Jun 10, 2025 | 1 year ago |
| SMA: Bullish | Jun 9, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 17, 2025 | 1 year ago |
| RSI: Oversold | Apr 15, 2025 | 1 year ago |
| RSI: Oversold | Apr 1, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 27, 2025 | 1 year ago |
| SMA: Bearish | Mar 12, 2025 | 1 year ago |
| SMA: Bullish | Mar 11, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 11, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 10, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 7, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 25, 2025 | 1 year ago |
| RSI: Oversold | Dec 30, 2024 | 1 year ago |
| MACD: Buy Signal | Dec 27, 2024 | 1 year ago |
| RSI: Oversold | Dec 10, 2024 | 1 year ago |
Key statistics
- Market cap
- 16.20M
- Enterprise value
- -7.36M
- Trailing P/E
- 0.00
- Forward P/E
- -0.43
- PEG ratio
- 0.00
- Price / sales
- 0.80
- Price / book
- 0.00
- EPS (TTM)
- -1.52
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 20.27M
- Revenue growth
- -11.60%
- Free cash flow
- -41.39M
- Total cash
- 28.13M
- Total debt
- 3.32M
- Return on equity
- -362.79%
- Shares outstanding
- 41.75M
- Short % of float
- 1.66%
- 50-day average
- 0.85396
- 200-day average
- 1.25
Analyst view
Consensus: hold
Hold
Price target (mean) 4.57 +652281.4% upside
Now 0.0007
- Target (low)
- 0.70
- Target (mean)
- 4.57
- Target (high)
- 12.00
Ratings (0m) 5 1 buy · 4 hold · 0 sell
- Strong buy0
- Buy1
- Hold4
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.19.
Financials — quick view
CARM Revenue — quarterly 0
CARM Net income — quarterly -9.77M
CARM EPS — quarterly -0.23
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.31 | -0.31 | 0.00 | 0.00% |
| Aug 8, 2024 | Jun 1, 2024 | -0.36 | -0.27 | +0.09 | +25.00% |
| May 9, 2024 | Mar 1, 2024 | -0.37 | -0.46 | -0.09 | -24.32% |
| Apr 1, 2024 | Dec 1, 2023 | -0.56 | -0.52 | +0.04 | +7.14% |
| Nov 9, 2023 | Sep 1, 2023 | -0.60 | -0.53 | +0.07 | +11.67% |
| Aug 10, 2023 | Jun 1, 2023 | -0.66 | -0.49 | +0.17 | +25.76% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 16, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
| Dec 12, 2024 | D. Boral Capital | main | Buy | Buy |
| Dec 12, 2024 | Baird | down | Outperform | Neutral |
| Dec 11, 2024 | Evercore ISI Group | down | Outperform | In-Line |
| Dec 10, 2024 | BTIG | down | Buy | Neutral |
| Dec 9, 2024 | D. Boral Capital | main | Buy | Buy |
About Carisma Therapeutics, Inc.
Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- carismatx.com
News
- Carmila: 2026 H1 Results
- Critical Review: Carisma Therapeutics (NASDAQ:CARM) vs. Protalex (OTCMKTS:PRTX)
- Carmila: 2025 Annual Results
- Financial Comparison: Context Therapeutics (NASDAQ:CNTX) vs. Carisma Therapeutics (NASDAQ:CARM)
- Carisma Announces Delisting from Nasdaq and SEC Deregistration
- Head-To-Head Survey: Achieve Life Sciences (NASDAQ:ACHV) vs. Carisma Therapeutics (NASDAQ:CARM)
- Carmanah Minerals Engages Warrior Drilling for Heritage Project; Targets Historic Eagle Zone on Burin Trend, NL
- Comparing Cassava Sciences (NASDAQ:SAVA) and Carisma Therapeutics (NASDAQ:CARM)
- 12 Health Care Stocks Moving In Friday's After-Market Session
- 12 Health Care Stocks Moving In Friday's Intraday Session
Your note
Sign in to keep a note on CARM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CANNELL THOMAS R | Chief Executive Officer | Conversion of Exercise of derivative security | Mar 1, 2023 | 672,386 |
| FORBES MONICA | Chief Financial Officer | Conversion of Exercise of derivative security | Mar 1, 2023 | 505,664 |
| HODITS REGINA | Director | Stock Award(Grant) | Mar 6, 2023 | 0 |
| KLICHINSKY MICHAEL | Officer | Stock Award(Grant) | Mar 6, 2023 | 484,347 |
| MACDONALD GLEN C. | Chief Technology Officer | Conversion of Exercise of derivative security | Mar 1, 2023 | 398,918 |
| MORRISON BRIGGS W. M.D. | Director | Stock Award(Grant) | Mar 6, 2023 | 12,175 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 3.47% | 1,448,247 | 561.92K | Sep 29, 2024 |
| Trustees of the University of Pennsylvania | 3.00% | 1,252,107 | 485.82K | Sep 29, 2024 |
| TPG GP A, LLC | 1.34% | 561,442 | 217.84K | Sep 29, 2024 |
| Barclays Plc | 1.32% | 549,305 | 213.13K | Sep 29, 2024 |
| Blackrock Inc. | 0.98% | 408,564 | 158.52K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.62% | 259,184 | 100.56K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.53% | 1,054,783 | 409.25K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.82% | 342,628 | 132.94K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.32% | 132,874 | 51.55K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.15% | 61,238 | 23.76K | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 0.11% | 47,703 | 18.51K | Aug 30, 2024 |
| Fidelity Total Market Index Fund | 0.10% | 40,366 | 15.66K | Oct 30, 2024 |